Nupathe - Innovating Neuroscience
  • Our Company
    • Message from the CEO
    • Management
    • Board of Directors
    • Mission & Strategy
    • Careers
      • Open Positions
      • Online Application
    • Contact Us
  • Pipeline
    • CNS Product Candidates
    • NP101 - Migraine
      • Learn more about Migraine
      • Learn more about MRN
    • NP201 - Parkinson's Disease
    • NP202 - Schizophrenia and Bipolar Disorder
    • Franchise Opportunities
    • Publications
    • Proprietary Delivery Technologies
      • SmartRelief
      • LAD
  • Partnering
    • Strategic Partnering
      • Partnering Opportunities
      • Current Collaborations
  • Investor Relations
  • Newsroom
    • Featured News
    • Press Releases
    • Media Resources
  • NuPathe Blog
    • Innovating Neuroscience
  • Migraine Resources
    • Migraine Resources
  • Careers
  • Contact Us
Investor Relations Overview
  • Overview
    • Driving Shareholder Value in NuPathe
    • The Migraine Market
    • CEO Q&A
    • CFO Q&A
  • Press Releases
  • Events and Presentations
  • Corporate Governance
    • Management
    • Board of Directors
  • SEC Filings
  • Stock Information
  • Analyst Coverage
  • Information Request
  • Annual Reports & Proxy Statements
  • Investor FAQs

Information Request

 *
 *
 *

 Security code
* Required Information
 
 

related links

  • NuPathe Blog
  • CEO Q&A
  • CFO Q&A
  • The Migraine Market
  • Driving Shareholder Value

Transfer Agent

Broadridge Corporate Issuer Solutions
1717 Arch St.
Philadelphia, PA 19103
(800) 733-1121
shareholder@broadridge.com
www.shareholder.broadridge.com
© Copyright 2012, NuPathe Inc. All rights reserved.
  • Terms of Use
  • Privacy Policy
  • Contact Us